Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Lymphoproliferative Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03340883
What this trial is testing

Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Chinook Therapeutics, Inc. 21
Testing effectiveness (Phase 2)UnknownNCT01300156
What this trial is testing

Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)

Who this might be right for
Hodgkin's Lymphoma
National Cancer Center, Korea 37
Early research (Phase 1)Looking for participantsNCT06830031
What this trial is testing

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell-lymphomaDLBCL, Nos Genetic SubtypesFollicular Lymphoma Grade 3B+3 more
Shanghai Exuma Biotechnology Ltd. 18
Testing effectiveness (Phase 2)Study completedNCT00793572
What this trial is testing

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Who this might be right for
Refractory Plasma Cell Myeloma
Fred Hutchinson Cancer Center 32
Testing effectiveness (Phase 2)WithdrawnNCT04535102
What this trial is testing

POLA+BR for Relapsed or Refractory DLBCL

Who this might be right for
Diffuse Large B Cell Lymphoma
University of Colorado, Denver
Early research (Phase 1)Study completedNCT01625351
What this trial is testing

CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

Who this might be right for
Ewing SarcomaGastrointestinal TumorGerm Cell Tumor+10 more
St. Jude Children's Research Hospital 23
Not applicableStudy completedNCT04872621
What this trial is testing

Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation

Who this might be right for
Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)
AstraZeneca 104
Testing effectiveness (Phase 2)Ended earlyNCT01125293
What this trial is testing

Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Who this might be right for
Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute 46
Testing effectiveness (Phase 2)Study completedNCT01116193
What this trial is testing

Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia

Who this might be right for
Leukemia, LymphoidPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Institut de Cancérologie de la Loire 10
Not applicableStudy completedNCT04135963
What this trial is testing

People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal)

Who this might be right for
Relapse and/or Refractory Multiple Myeloma
Takeda 62
Very early researchEnded earlyNCT04034446
What this trial is testing

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Who this might be right for
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China 2
Early research (Phase 1)WithdrawnNCT05519527
What this trial is testing

STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis

Who this might be right for
Refractory T Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)UnknownNCT01354457
What this trial is testing

Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+

Who this might be right for
Acute Lymphoblastic Leukemia
Nantes University Hospital 21
Early research (Phase 1)WithdrawnNCT05487495
What this trial is testing

Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma

Who this might be right for
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Beijing Boren Hospital
Testing effectiveness (Phase 2)Study completedNCT00276003
What this trial is testing

INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.

Who this might be right for
Non-Hodgkin's LymphomaCancer
University of New Mexico 22
Testing effectiveness (Phase 2)Study completedNCT01492088
What this trial is testing

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Who this might be right for
Relapsed or Refractory Hodgkin LymphomaRelapsed or Refractory Anaplastic Large-cell Lymphoma
Millennium Pharmaceuticals, Inc. 36
Early research (Phase 1)Study completedNCT00004862
What this trial is testing

Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Who this might be right for
Leukemia
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Looking for participantsNCT05643742
What this trial is testing

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
B-cell LymphomaNon-Hodgkin LymphomaB-cell Malignancy+5 more
CRISPR Therapeutics AG 120
Early research (Phase 1)Ended earlyNCT02702141
What this trial is testing

A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin LymphomaDLBCLDiffuse Large B-cell Lymphoma+1 more
Seagen Inc. 44
Early research (Phase 1)Ended earlyNCT03755154
What this trial is testing

Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

Who this might be right for
Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Non-Hodgkin LymphomaRelapsed or Refractory Multiple Myeloma+1 more
Institut de Recherches Internationales Servier 60
Next Page